Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a report published on Tuesday morning, Benzinga reports. The brokerage currently has a $50.00 target price on the biotechnology company’s stock.

Other analysts have also recently issued reports about the stock. Stephens initiated coverage on shares of Actinium Pharmaceuticals in a report on Tuesday, May 14th. They set an overweight rating and a $25.00 target price for the company. Maxim Group upped their price objective on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a buy rating in a research note on Tuesday, March 19th. Cantor Fitzgerald reiterated an overweight rating and set a $21.00 target price on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. Finally, StockNews.com upgraded Actinium Pharmaceuticals from a sell rating to a hold rating in a research report on Sunday, May 5th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $25.60.

Actinium Pharmaceuticals Price Performance

Shares of ATNM opened at $8.44 on Tuesday. The firm has a market capitalization of $251.19 million, a P/E ratio of -4.93 and a beta of 0.08. Actinium Pharmaceuticals has a one year low of $4.00 and a one year high of $10.24.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last released its quarterly earnings results on Friday, April 26th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. Equities research analysts predict that Actinium Pharmaceuticals will post -1.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ATNM. Virtu Financial LLC grew its holdings in Actinium Pharmaceuticals by 319.2% during the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the biotechnology company’s stock valued at $642,000 after buying an additional 62,459 shares in the last quarter. Vanguard Group Inc. grew its stake in Actinium Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the biotechnology company’s stock valued at $11,325,000 after acquiring an additional 82,113 shares in the last quarter. Sanders Morris Harris LLC purchased a new position in Actinium Pharmaceuticals during the first quarter valued at $78,000. Creative Financial Designs Inc. ADV increased its holdings in Actinium Pharmaceuticals by 19.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 3,175 shares during the last quarter. Finally, Brandywine Global Investment Management LLC purchased a new stake in Actinium Pharmaceuticals in the 3rd quarter worth $1,033,000. 27.50% of the stock is owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.